stockrow
Saturday 7 November 2026
Export STTK’s income statement to Excel — free account
Shattuck Labs, Inc.
STTK Healthcare Biotechnology
Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.
- Revenue
- −10.3%
- EPS
- +50.0%
- Free cash flow
- +1.01%
Quarter to June 2026, against a year earlier
4.59
0.10
+2.23%
Follow STTK
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 30.77 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (19.32) | |
P/B ratio |
— | — | — | 1.85 | |
Price to Tangible BV |
— | — | — | 1.85 | |
EV/Sales |
— | — | — | 15.41 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (1.77) | |
EV/FCF |
— | — | — | (1.77) | |
Quick Ratio |
26.94 | 21.28 | 11.07 | 16.14 | |
Current Ratio |
27.59 | 22.06 | 11.70 | 17.00 | |
Net Debt/EBITDA |
13.44 | 6.15 | 6.12 | 8.64 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.05 | |
Operating CF/Net income |
0.67 | 0.91 | 0.67 | 0.89 | |
Capex/Depreciation |
(0.21) | 0.00 | 0.00 | (0.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 761.80% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 409.80% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 177.80% | |
Graham Net Nets |
— | — | — | 0.48 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (42.68%) | |
Free Cash Flow Yield |
— | — | — | (28.34%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.08) | (0.12) | (0.12) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.12) | (0.12) | (0.12) | |
Cash per Share |
1.61 | 0.81 | 1.12 | 1.19 | |
Shareholders Equity per Share |
1.63 | 0.85 | 1.18 | 1.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.63 | 0.85 | 1.18 | 1.29 | |
Free Cash Flow |
(10.33) | (13.42) | (8.49) | (9.00) | |
Working Capital |
205.54 | 89.50 | 75.42 | 85.39 | |
Capital Expenditures |
(0.14) | — | 0.00 | (0.07) | |
Net Current Asset Value |
203.74 | 87.47 | 73.84 | 83.63 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.07 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
2.21 | 1.39 | 2.26 | 2.04 | |
Average Assets |
142.52 | 89.64 | 91.04 | 106.03 | |
Average Common Equity |
134.08 | 81.71 | 81.01 | 94.91 |
Columns are period end dates